microdosing glp 1 weight loss GLP-1s: What You Should Know Microdosing GLP-1 Drugs: What To

GHK-Cu Monitoring Schedule: Labs & Exams You Need At a glance Drug / GHK-Cu is a tripeptide-copper(II) complex first isolated from human plasma albumin Route / subcutaneous injection or topical (compounded under FDA section 503A) Baseline labs / serum copper, ceruloplasmin, CBC with differential, CMP including liver enzymes Recheck interval / 4 weeks after initiation, then every 8 to 12 weeks Normal serum copper / 70 to 140 g/dL (11 to 22 mol/L) Ceruloplasmin target / 20 to 35 mg/dL Liver enzymes / ALT and AST should remain below 2x upper limit of normal 24-hour urine copper / ordered if serum copper exceeds 155 g/dL on two consecutive draws Skin exam / baseline and every 12 weeks for subcutaneous injection sites Discontinuation trigger / serum copper above 200 g/dL or ceruloplasmin below 15 mg/dL How GHK-Cu Works: Mechanism Before Monitoring GHK-Cu is glycyl-L-histidyl-L-lysine bound to a single copper(II) ion

We don't just prescribe

Semaglutide which has a FDA approval is the GLP-1 receptor agonist, another anti-obesity medication currently available for long-term use for weight loss

Y.SiadatS

4 (leaky gut) : ,